Blueprint Medicines Co. (NASDAQ:BPMC) Given Average Recommendation of “Moderate Buy” by Analysts

Blueprint Medicines Co. (NASDAQ:BPMC) has received a consensus recommendation of “Moderate Buy” from the eighteen ratings firms that are covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $126.56.

BPMC has been the subject of several research analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Wedbush reaffirmed an “outperform” rating and set a $128.00 price target on shares of Blueprint Medicines in a research note on Thursday, May 1st. Scotiabank began coverage on shares of Blueprint Medicines in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $150.00 price objective on the stock. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, May 2nd. Finally, Piper Sandler upped their price target on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a report on Monday, January 27th.

Insiders Place Their Bets

In related news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the sale, the chief operating officer now owns 69,266 shares in the company, valued at approximately $6,581,655.32. The trade was a 3.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ariel Hurley sold 2,752 shares of the stock in a transaction on Monday, May 5th. The shares were sold at an average price of $103.13, for a total transaction of $283,813.76. Following the transaction, the insider now owns 16,944 shares in the company, valued at $1,747,434.72. This trade represents a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,503 shares of company stock worth $1,027,931 in the last quarter. 4.21% of the stock is owned by corporate insiders.

Institutional Trading of Blueprint Medicines

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Blueprint Medicines by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company’s stock valued at $590,905,000 after acquiring an additional 91,450 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Blueprint Medicines by 5.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,679,089 shares of the biotechnology company’s stock valued at $495,331,000 after purchasing an additional 291,822 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Blueprint Medicines by 8.0% during the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company’s stock worth $373,421,000 after purchasing an additional 316,754 shares during the period. William Blair Investment Management LLC lifted its position in shares of Blueprint Medicines by 16.1% in the 4th quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company’s stock worth $169,616,000 after buying an additional 269,896 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Blueprint Medicines by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,490,101 shares of the biotechnology company’s stock valued at $129,996,000 after buying an additional 9,914 shares during the period.

Blueprint Medicines Price Performance

Blueprint Medicines stock opened at $97.74 on Friday. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines has a one year low of $73.04 and a one year high of $121.90. The company has a market cap of $6.31 billion, a P/E ratio of -90.50 and a beta of 0.83. The business has a fifty day moving average of $88.49 and a two-hundred day moving average of $93.74.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The company had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. During the same quarter last year, the business earned $1.40 EPS. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. As a group, analysts predict that Blueprint Medicines will post -1.28 earnings per share for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.